Baclofen for the treatment of alcohol use disorder in patients with liver cirrhosis: 10 years after the first evidence

Carolina Mosoni, Tommaso Dionisi, Gabriele Angelo Vassallo, Antonio Mirijello, Claudia Tarli, Mariangela Antonelli, Luisa Sestito, Maria Margherita Rando, Alberto Tosoni, Salvatore De Cosmo, Antonio Gasbarrini, Giovanni Addolorato

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Alcohol Use Disorder (AUD) is a chronic and relapsing condition characterized by harmful alcohol intake and behavioral-cognitive changes. AUD is the most common cause of liver disease in the Western world. Alcohol abstinence is the cornerstone of therapy in alcoholic patients affected with liver disease. Medical recommendations, brief motivational interventions and psychosocial approach are essential pieces of the treatment for these patients; however, their efficacy alone may not be enough to achieve total alcohol abstinence. The addition of pharmacological treatment could improve clinical outcomes in AUD patients. Moreover, pharmacological treatments for AUD are limited in patients with advanced liver disease, since impaired liver function affects drugs metabolism and could increase the risk of drugs-related hepatotoxicity. At present, only baclofen has been tested in RCTs in patients with advanced liver disease. This medication was effective to reduce alcohol intake, to promote alcohol abstinence and to prevent relapse in AUD patients affected by liver cirrhosis. In addition, the drug showed a safe profile in these patients. In this review, clinical studies about efficacy and safety of baclofen administration in patients with AUD and advanced liver disease will be reviewed. Open question about the most appropriate dose of the drug, duration of the treatment and need of additional studies will also be discussed.

Original languageEnglish
Article number474
JournalFrontiers in Psychiatry
Volume9
Issue numberOCT
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Baclofen
Liver Cirrhosis
Alcohols
Liver Diseases
Alcohol Abstinence
Therapeutics
Pharmaceutical Preparations
Pharmacology
Western World
Alcoholics
Safety
Recurrence
Liver

Keywords

  • Alcohol use disorder
  • Alcoholic liver disease
  • Baclofen
  • GABA-B receptor
  • Liver cirrhosis

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Baclofen for the treatment of alcohol use disorder in patients with liver cirrhosis : 10 years after the first evidence. / Mosoni, Carolina; Dionisi, Tommaso; Vassallo, Gabriele Angelo; Mirijello, Antonio; Tarli, Claudia; Antonelli, Mariangela; Sestito, Luisa; Rando, Maria Margherita; Tosoni, Alberto; De Cosmo, Salvatore; Gasbarrini, Antonio; Addolorato, Giovanni.

In: Frontiers in Psychiatry, Vol. 9, No. OCT, 474, 01.10.2018.

Research output: Contribution to journalReview article

Mosoni, Carolina ; Dionisi, Tommaso ; Vassallo, Gabriele Angelo ; Mirijello, Antonio ; Tarli, Claudia ; Antonelli, Mariangela ; Sestito, Luisa ; Rando, Maria Margherita ; Tosoni, Alberto ; De Cosmo, Salvatore ; Gasbarrini, Antonio ; Addolorato, Giovanni. / Baclofen for the treatment of alcohol use disorder in patients with liver cirrhosis : 10 years after the first evidence. In: Frontiers in Psychiatry. 2018 ; Vol. 9, No. OCT.
@article{edbf85e6c8514af2a0c3a72699dcb5d4,
title = "Baclofen for the treatment of alcohol use disorder in patients with liver cirrhosis: 10 years after the first evidence",
abstract = "Alcohol Use Disorder (AUD) is a chronic and relapsing condition characterized by harmful alcohol intake and behavioral-cognitive changes. AUD is the most common cause of liver disease in the Western world. Alcohol abstinence is the cornerstone of therapy in alcoholic patients affected with liver disease. Medical recommendations, brief motivational interventions and psychosocial approach are essential pieces of the treatment for these patients; however, their efficacy alone may not be enough to achieve total alcohol abstinence. The addition of pharmacological treatment could improve clinical outcomes in AUD patients. Moreover, pharmacological treatments for AUD are limited in patients with advanced liver disease, since impaired liver function affects drugs metabolism and could increase the risk of drugs-related hepatotoxicity. At present, only baclofen has been tested in RCTs in patients with advanced liver disease. This medication was effective to reduce alcohol intake, to promote alcohol abstinence and to prevent relapse in AUD patients affected by liver cirrhosis. In addition, the drug showed a safe profile in these patients. In this review, clinical studies about efficacy and safety of baclofen administration in patients with AUD and advanced liver disease will be reviewed. Open question about the most appropriate dose of the drug, duration of the treatment and need of additional studies will also be discussed.",
keywords = "Alcohol use disorder, Alcoholic liver disease, Baclofen, GABA-B receptor, Liver cirrhosis",
author = "Carolina Mosoni and Tommaso Dionisi and Vassallo, {Gabriele Angelo} and Antonio Mirijello and Claudia Tarli and Mariangela Antonelli and Luisa Sestito and Rando, {Maria Margherita} and Alberto Tosoni and {De Cosmo}, Salvatore and Antonio Gasbarrini and Giovanni Addolorato",
year = "2018",
month = "10",
day = "1",
doi = "10.3389/fpsyt.2018.00474",
language = "English",
volume = "9",
journal = "Frontiers in Psychiatry",
issn = "1664-0640",
publisher = "Frontiers Research Foundation",
number = "OCT",

}

TY - JOUR

T1 - Baclofen for the treatment of alcohol use disorder in patients with liver cirrhosis

T2 - 10 years after the first evidence

AU - Mosoni, Carolina

AU - Dionisi, Tommaso

AU - Vassallo, Gabriele Angelo

AU - Mirijello, Antonio

AU - Tarli, Claudia

AU - Antonelli, Mariangela

AU - Sestito, Luisa

AU - Rando, Maria Margherita

AU - Tosoni, Alberto

AU - De Cosmo, Salvatore

AU - Gasbarrini, Antonio

AU - Addolorato, Giovanni

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Alcohol Use Disorder (AUD) is a chronic and relapsing condition characterized by harmful alcohol intake and behavioral-cognitive changes. AUD is the most common cause of liver disease in the Western world. Alcohol abstinence is the cornerstone of therapy in alcoholic patients affected with liver disease. Medical recommendations, brief motivational interventions and psychosocial approach are essential pieces of the treatment for these patients; however, their efficacy alone may not be enough to achieve total alcohol abstinence. The addition of pharmacological treatment could improve clinical outcomes in AUD patients. Moreover, pharmacological treatments for AUD are limited in patients with advanced liver disease, since impaired liver function affects drugs metabolism and could increase the risk of drugs-related hepatotoxicity. At present, only baclofen has been tested in RCTs in patients with advanced liver disease. This medication was effective to reduce alcohol intake, to promote alcohol abstinence and to prevent relapse in AUD patients affected by liver cirrhosis. In addition, the drug showed a safe profile in these patients. In this review, clinical studies about efficacy and safety of baclofen administration in patients with AUD and advanced liver disease will be reviewed. Open question about the most appropriate dose of the drug, duration of the treatment and need of additional studies will also be discussed.

AB - Alcohol Use Disorder (AUD) is a chronic and relapsing condition characterized by harmful alcohol intake and behavioral-cognitive changes. AUD is the most common cause of liver disease in the Western world. Alcohol abstinence is the cornerstone of therapy in alcoholic patients affected with liver disease. Medical recommendations, brief motivational interventions and psychosocial approach are essential pieces of the treatment for these patients; however, their efficacy alone may not be enough to achieve total alcohol abstinence. The addition of pharmacological treatment could improve clinical outcomes in AUD patients. Moreover, pharmacological treatments for AUD are limited in patients with advanced liver disease, since impaired liver function affects drugs metabolism and could increase the risk of drugs-related hepatotoxicity. At present, only baclofen has been tested in RCTs in patients with advanced liver disease. This medication was effective to reduce alcohol intake, to promote alcohol abstinence and to prevent relapse in AUD patients affected by liver cirrhosis. In addition, the drug showed a safe profile in these patients. In this review, clinical studies about efficacy and safety of baclofen administration in patients with AUD and advanced liver disease will be reviewed. Open question about the most appropriate dose of the drug, duration of the treatment and need of additional studies will also be discussed.

KW - Alcohol use disorder

KW - Alcoholic liver disease

KW - Baclofen

KW - GABA-B receptor

KW - Liver cirrhosis

UR - http://www.scopus.com/inward/record.url?scp=85055278620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055278620&partnerID=8YFLogxK

U2 - 10.3389/fpsyt.2018.00474

DO - 10.3389/fpsyt.2018.00474

M3 - Review article

AN - SCOPUS:85055278620

VL - 9

JO - Frontiers in Psychiatry

JF - Frontiers in Psychiatry

SN - 1664-0640

IS - OCT

M1 - 474

ER -